



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/648,800	08/27/2003	Gisbert Depke	SCH-1920	3937
23599	7590 07/13/2005	-	EXAMINER	
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.			FEDOWITZ, MATTHEW L	
2200 CLARE	NDON BLVD.			
<b>SUITE 1400</b>			ART UNIT	PAPER NUMBER
ARLINGTON	I, VA 22201		1623	
			DATE MAILED: 07/13/200:	5

Please find below and/or attached an Office communication concerning this application or proceeding.

<del> </del>	Application No.	Applicant(s)	·
	10/648,800	DEPKE ET AL.	
Office Action Summary	Examiner	Art Unit	
	Matthew L. Fedowitz	1623	
The MAILING DATE of this commun Period for Reply	ication appears on the cover sheet w	ith the correspondence address	
A SHORTENED STATUTORY PERIOD F THE MAILING DATE OF THIS COMMUNI  - Extensions of time may be available under the provisions after SIX (6) MONTHS from the mailing date of this comm  - If the period for reply specified above is less than thirty (3  - If NO period for reply is specified above, the maximum states are to reply within the set or extended period for reply Any reply received by the Office later than three months a earned patent term adjustment. See 37 CFR 1.704(b).	ICATION. s of 37 CFR 1.136(a). In no event, however, may a nunication. s0) days, a reply within the statutory minimum of thir atutory period will apply and will expire SIX (6) MON will, by statute, cause the application to become Al	reply be timely filed  ty (30) days will be considered timely.  ITHS from the mailing date of this communication.  BANDONED (35 U.S.C. § 133).	
Status	•		
1) Responsive to communication(s) file	ed on <u>02 May 2005</u> .		
2a) ☐ This action is <b>FINAL</b> .	2b)☐ This action is non-final.		
3) Since this application is in condition closed in accordance with the practi	·		
Disposition of Claims			
4) Claim(s) 1,4-8 and 10-17 is/are pend 4a) Of the above claim(s) is/a  5) Claim(s) is/are allowed.  6) Claim(s) is/are rejected.  7) Claim(s) is/are objected to.  8) Claim(s) 1,4-8 and 10-17 are subjected.	re withdrawn from consideration.	ement.	
Application Papers		•	
9) The specification is objected to by th	e Examiner.	•	
10) The drawing(s) filed on is/are:	a) accepted or b) objected to	by the Examiner.	
Applicant may not request that any obje			
Replacement drawing sheet(s) including 11) The oath or declaration is objected to	•	d Office Action or form PTO-152.	
Priority under 35 U.S.C. § 119		•	
<ul><li>2.  Certified copies of the priority</li><li>3.  Copies of the certified copies</li></ul>	documents have been received.  documents have been received in A of the priority documents have been onal Bureau (PCT Rule 17.2(a)).	Application No received in this National Stage	
Attachment(s)			
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (F</li> </ol>		Summary (PTO-413) s)/Mail Date	
3) Information Disclosure Statement(s) (PTO-1449 or Paper No(s)/Mail Date	[ ]	nformal Patent Application (PTO-152)	

Application/Control Number: 10/648,800

Art Unit: 1623

### **DETAILED ACTION**

Claims 1,4-8 and 10-17 are pending in this action.

### Claim Rejections - 35 USC § 112

Applicant's amendments have overcome the 35 U.S.C. 112 second paragraph rejection.

## Claim Rejections - 35 USC § 101

Applicant's amendments have overcome the 35 U.S.C. 101 rejection.

### Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1, 4-8, 11 and 13-15 drawn to treating or prophylaxis of radical-mediated cell injuries, treat/prevent a disease caused by peroxynitrite-mediated reactions, classified in class 514, subclass 410.
- II. Claims 10, 12 and 17, drawn to a pharmaceutical composition, classified in class540, subclass 145.
- III. Claim 16, drawn to a method of diagnosing a disease, classified in class 424, subclass 9.361.

The Groups I through III are separate and patentably distinct because there is no patentable co-action among them and a reference anticipating one member will not render another obvious..

Because the inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and different classification, a search of the three groups designated above would impose an undue burden upon the examiner, and restriction for examination purposes is indicated as proper.

Application/Control Number: 10/648,800

Art Unit: 1623

Claims 1, 4-7 and 10-17 generic to a plurality of disclosed patentably distinct species comprising methods of treatment or prophylaxis of radical mediated cell injuries, pharmaceutical compositions and diagnostic agents relating to porphyrin-based compounds. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR

Application/Control Number: 10/648,800 Page 4

Art Unit: 1623

1.143). Furthermore, the applicant is encouraged to resubmit the claim in a format that is readable on the elected species.

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Matthew L. Fedowitz whose telephone number is (571) 272-3105. If attempts to reach the examiner by telephone are unsuccessful, the examiner's primary, James O. Wilson, can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Matthew L. Fedowitz, Pharm.D., Esq.

James O. Wilson, Supervisory Patent Examiner

Art Unit 1623